CVKD | tickerfilter.com

Fundamental analysis

37%

Profitability 35%

Dept financing 24%

Liquidity 50%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-3.61%

1 Month

44.76%

3 Months

-16.62%

6 Months

-38.07%

1 Year

-50.86%

2 Year

1,184.32%

Key data

Stock price

$8.28

P/E Ratio

0.00

DAY RANGE

$7.83 - $8.30

EPS

-$9.01

52 WEEK RANGE

$4.91 - $20.39

52 WEEK CHANGE

-$46.30

MARKET CAP

28.269 M

YIELD

N/A

SHARES OUTSTANDING

0.000

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-08-2025

BETA

1.42

PUBLIC FLOAT

AVERAGE 10 VOLUME

$60,335

AVERAGE 30 VOLUME

$54,130

Company detail

CEO: Quang Pham
Region: US
Website: www.cadrenal.com
Employees: 0
IPO year: 2023

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

We are focused on developing tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease, or ESRD, and atrial fibrillation (irregular heartbeat), or AFib. Our principal executive offices are located at 822 A1A North, Suite 306, Ponte Vedra, Florida.

CVKD - Cadrenal Therapeutics, Inc.